Biphenyl Imidazole Compounds

Elder Pharmaceuticals Ltd
Granted App No 1856/MUM/2008 Patent 262726 Pharmaceuticals

Patent information

IP India · live record
Application number
1856/MUM/2008
Filing date
02 September 2008
Status
Granted
Legal status
Ceased
Publication number
31/2010
Publication type
INA
Invention field
Pharmaceuticals
Patent number
262726
Grant date
09 September 2014
Next renewal due
09 December 2014Overdue

Abstract

Biphenyl compounds of Formula I: are novel compounds, their pharmaceuticall y acceptable salts or solvates and their pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicines to treat inflammation and process for preparing the same, and novel use of the compounds of Formula II to treat inflammation in any living bodies.

Applicants

1
India
ELDER PHARMACEUTICALS LTD ELDER HOUSE, PLOT NO C/9, DALIA INDL. ESTATE, OFF. NEW LINK ROAD, ANDHERI WEST, MUMBAI,

Inventors

4
India
SAKHARDANDE RAJIV RAWALNATH8, DIPTI, HANUMAN CROSS ROAD NO 1, VILEPARLE EAST, MUMBAI-400057,
India
KULKARNI VITHAL MADHVARAOB-302, MONT VERT ALTESSE, SUS ROAD, PASHAN, PUNE-411021,
India
WAGH NILESH KHANDUOM GURUDEV, PLOT NO 23, BHAUSAHEB HIRE SOCIETY, HIRAWADI, PANCHAVATI, NASIK-422003,
India
NIMBALKAR MANMOHAN MADHAVRAO46, UTKARSH SAYANI ROAD, KHED GALLI, PRABHADEVI, MUMBAI-400025,

Specification

Show full textCollapse

FORM 2 THE PATENT ACT 1970 (39 of 1970) & The Patents Rules, 2003 PROVISIONAL SPECIFICATION (See section 10 and rule 13) 1. TITLE OF THE INVENTION Anti inflammatory compounds. 2. APPLICANT (S) (a) NAME : ELDER PHARMACEUTICALS LTD. (b) NATIONALITY : INDIAN (c) ADDRESS : Elder House, Plot No. C/9, Dalia Indl. Estate, Off. New Link Road, Andheri (W), Mumbai-400 058,. India 3. PREAMBLE TO THE DESCRIPTION The following specification describes the invention.

1856 2 SEP 2008

4. DESCRIPTION: FIELD OF THE INVENTION: The present invention relates to the novel compounds and known compounds and its pharmaceutically acceptable salts, and its solvates, to a process for preparing such compounds, to pharmaceutical compositions containing compounds and to the use of such compounds and composition in reducing the inflammation in living bodies. This invention particularly relates to novel compounds of the general Formula I:

Formula I: and its pharmaceutically acceptable salts, and its solvates, to a process for preparing such compounds, to pharmaceutical compositions containing compounds and to the use of such compounds and composition in medicines. The invention also relates to use compounds of Formula II for treating inflammation in living bodies. 2

Formula II BACKGROUND OF THE INVENTION: Inflammation is a complex stereotypical reaction of the body expressing the response to damage of its cells and vascularized tissues. The inflammatory process is designed to provide a rapid mechanism by which the host can respond to the invasion of foreign material and return to homeostatic equilibrium. The biosynthetic cascade of arachidonic acid has been the object of intense research. Arachidonic acid is present in cell membranes as esters of phosphorylated glycerides, the so-called phospho¬lipids. Under some defined biological stimulus, certain lipases can hydrolyze, either directly or in stepwise fashion, these phosphorylated arachidonic glycerides to release free arachidonic acid. The lipases that perform such function, most prominent is the enzyme Phopholipase A2; this enzyme hydrolyzes the phospholipids and releases arachidonic acid in a single step. Arachidonic acid liberated from phospholipids by various stimulants, can be metabolized by a group of enzymes such as (a) arachidonoyl-CoA synthetase and arachidonoyl -CoA:lyophospholipid transferase reincorporate arachidonic acid back onto phospholipids, (b) the cyciooxygenase (COX) which are further sub divided mainly into cyclooxygehase-1 (COX-1) and cyclooxygenase-2 (COX-2) pathway to pro-inflammatory prostaglandins (PGs) and thromboxane A2 (c) lipoxygenase (LOX) pathways to hydroperoxy eicosatetraenoic acids (HPETEs), hydroxy eicosatetraenoic acids (HETEs) and leukotrienes (LTs). Lipoxygenases exist in three lipoxygenases (5-lipoxygenase, 12-lipoxygenase, 15-lipoxygenase), and the most prominent is 5-lipoxygenase. 5-Lipoxygenase metabolises 3

arachidonic acid into leukotrienes. Zileuton is an example of 5-iipoxygenase inhibitor, belonging to the N-hydroxyurea class of compounds. 5-Lipoxygenase operates in a much more complex way. For 5-lipoxygenase to be effective, it needs the cofaclors Ca2+, ATP and another protein nicknamed 5-FLAP (5-Lipoxygenase activating protein), a membrane protein. 5-Lipoxygenase relocates to the membrane binding with the three cofactors mentioned and starts the transformation of arachidonic acid eventually to result in leukotrienes. Inhibitors of the 5-FLAP are effective anti-inflammatory compounds switching off the 5-lipoxygenase chain. Among the 5-FLAP inhibitors may be mentioned, MK-866, (±) 2-fluoro-a-methyl-1,l'-biphenyl]-4-acetic acid. (Novel Inhibitors of Leukotriene, Edited by G. Folco, B, Samuelson, R. C. Murphy, Birkhlauser Verlag, Basel, 1999), (d) cytochrome P450 pathways to an epoxide, epoxyeicosatrienoic acid which further is converted to diols through the agency of epoxide hydrolases, (e) diffusion of arachidonic acid outside the cell. Finally arachidonic acid can also be transformed into its ethanol amide, called Anadamide, identified as an endogenous ligand for cannabinoid receptors in brain cells. Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) namely, indomethacin, flurbiprofen, ketoprofen, ketorolac, diclofenac and tolfenamic acid are used as first line therapy for relieving pain and inflammation. Chronic use of these drugs has been associated with the propensity for side effects such as gastrointestinal irritation (mucosal damage, bleeding) and also at the renal level, thereby limiting their therapeutic potential. In order to overcome these side effects, worldwide research activities focused on developing safer NSAIDs- as selective COX-2 inhibitors. Several selective COX-2 inhibiting drugs such as Celecoxib (J. Med.Chem. 1997, 40(9), 1347-1365), Rofecoxib (Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778), Valdecoxib (J. Med Chem. 2000, 43(5), 775-777), Parecoxib Na (J. Med Chem. 2000, 43(9), 1661-1663) and etoricoxib (J. Pharmacol. Exp. Ther. 2002,296(2), 558-566) are being marketed as a new generation of NSAIDs. Some of these NSAIDs are represented in (Fig:A) 4

CH3OH

Ketoprofen

Indomethacin

Flurbiprofen

H CH3 .N 3

COOH

COOH

Diclofenac

Tolfenamic acid

H3C O

O O

H3C. O O'

Rofecoxib

Celecoxib

Etoricoxib

Fig A. Chemical structures of NSAIDs and selective COX-2 inhibitors. However, some of selective COX-2 inhibitors were found having similar side effects on edema, hypertension as of conventional NSAIDs and the potentially increased risk of thrombosis associated with these inhibitors (N. Eng. J. Med 2000, 343:1520-1528). While gastrointestinal safety of NSAIDs is a major limitation to the use of this class of drugs, there is an increased concern about their cardiovascular adverse effects. All such and other drawbacks associated with some of existing COX-2 drugs resulted in the withdrawal of 5

rofecoxib (Vioxx; Merck & Co, Inc, Whitehouse Station, NJ) in particular, from worldwide markets. Thus it is an issue of the importance of targeting selectivity for COX-2 and/or COX-1 (Circulation 2004, 109, 2068-2073). Although several NSAIDs are in clinical practice even now, their use has been limited due to unwanted side effects. Discovery of an effective NSAID, which would be free from gastrointestinal irritation, ulcerogenicity, etc. make the research work a challenging task which ultimately is the aim of new drug development. The present investigation is aimed for the development of novel and NSAID useful for the treatment of various types of pain and inflammatory disorder. These molecules were designed on the basis of 3-D-Quantitative structure-activity relationship (QSAR) and molecular modeling studies performed on a known NSAIDs (J. Chem. Inf. Model., 2007, 47 (2), 635 -643). The results encouraged inventors to synthesis and screened for anti inflammatory activity against Carrageenan-induced rat paw edema model. OBJECTIVE OF THE INVENTION The main object of the present invention relates to the development of novel biphenyl imidazole compounds and use of these compounds to treat inflammatory disorders. Novel use of compounds of Formula II to treat any inflammation in the living bodies. Object of the present invention is to overcome the side effects of the existing NSAIDs. such as gastrointestinal irritation, ulcerogenicity. with improved anti inflammatory effect. 6

SUMMARY OF THE INVENTION: The compounds of Formula I:

Formula I Where in, Imidazole ring is substituted with one or more of Rl group, Where in, Rl is H, -NO2, R4, -O-R4, -NH2, -SO2NH2, -NHSO2-R4, halo, -COOH, -CHO, -CN; R2 is H, -O-(CH2)n-R4 where in n = 0 to 5, - NO2, -SO2NH2, -NHSO2-R4, -CN, -COOH, halo, optionally substituted amino group, R4, cyclo alkyl group, alkyl thio, acyl group, substituted or unsubstituted heterocyclic group, alkoxy carbonyl, aryloxy, aryloxy carbonyl, substituted or unsubstituted amide; R3 is H: R4 is any substituted or unsubstituted alkyl; are novel compounds and their pharmaceutically acceptable salts or solvates. Pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicines to treat inflammation and process for preparing the same and novel use of compounds of Formula II: 7

Formula II where in, R5 is one or more of H, halo, NO2, R4, alkoxy carbonyl, -0-(CH2)n-R4 where in n is 0 to 5, COOH, -SO2NH2, -NHSO2-R4, aryl, cycloalkyJ, benzyl or substituted benzyl optionally substituted on phenyl ring with atleast one halogen, CN, -(CH2)m-R7 where in m is 0 to 5, - (CH2)p-OC(O)R4 where in p isl to 5, substituted or unsubstituted amine; R6 is one or more of CN, H, halo, NO2, R4, alkoxy carbonyl. -0-(CH2)n-R4 where in n is 0 to 5, -COOH, -SO2NH2, -NHSO2-R4, SO2-NH-R4, aryl, substituted or unsubstituted heterocyclic group, -CH2COOH, -CH2COOR4, -SO3H, -PO3H, substituted or unsubstituted amide, -CH2-R7, -CONH-R7 where in R7 is any substituted or unsubstituted heterocyclic group; R4 is any substituted or unsubstituted alky]. Compounds of this invention are significantly superior to compounds of known NSAID.

5. CLAIMS We claim, 1. Novel compounds of the Formula: I R1

.N.

in which, Imidazole ring is substituted with one or more of Rl group, Where in, Rl is H, - NO2, R4, - O-R4, -NH2, -SO2NH2, -NHSO2-R4, halo, -COOH, -CHO, -CN; R2 is H, - O-(CH2)n-R4 where in n = 0 to 5, -NO2, -SO2NH2, -NHSO2-R4, -CN, -COOH, halo, optionally substituted amino group, R4, cyclo alkyl group, alkyl thio, acyl group, substituted or unsubstituted heterocyclic group, alkoxy carbonyl, aryloxy, aryloxy carbonyl, substituted or unsubstituted amide; R3 is H; R4 is any substituted or unsubstituted alkyl. 2. Use of compounds of Formula II to treat inflammation in living bodies. 9

6. SIGNATURE and DATE R5 is one or more of H, halo, NO2, R4, alkoxy carbonyl, - 0-(CH2)n-R4 where in n is 0 to 5, -COOH, - SO2NH2) -NHS02-R4, aryl, cycloalkyl, benzyl or substituted benzyl optionally substituted on phenyl ring with atleast one halogen, CN, -(CH2)m-R7 where in m is 0 to 5, -(CH2)p-OC(0)R4 where in p isl to 5, substituted or unsubstituted amine; R6 is one or more of CN, H, halo, NO2, R4, alkoxy carbonyl, -0-(CH2)n-R4 where in n is 0 to 5, -COOH, -SO2NH2, -NHSO2-R4, SO2-NH-R4, aryl, substituted or unsubstituted heterocyclic group, -CH2COOH, -CH2COOR4, -S03H, -P03H, substituted or unsubstituted amide, -CH2-R7 where in R7 is any substituted or unsubstituted heterocyclic group, -CONH-R7; R4 is any substituted or unsubstituted alkyl. 10

Documents

Sign in to open
Application documents
1 1856-MUM-2008-FORM 3(24-10-2011).pdf 24 Oct 2011
2 1856-MUM-2008-CORRESPONDENCE(24-10-2011).pdf 24 Oct 2011
3 1856-MUM-2008-ANNEXURE I TO III(24-10-2011).pdf 24 Oct 2011
4 1856-MUM-2008-FORM 3(27-11-2012).pdf 27 Nov 2012
5 1856-MUM-2008-CORRESPONDENCE(27-11-2012).pdf 27 Nov 2012
6 1856-MUM-2008-ANNEXURE III(27-11-2012).pdf 27 Nov 2012
7 1856-MUM-2008-ANNEXURE II(27-11-2012).pdf 27 Nov 2012
8 1856-MUM-2008-ANNEXURE I(27-11-2012).pdf 27 Nov 2012
9 1856-MUM-2008_EXAMREPORT.pdf 09 Aug 2018
10 1856-MUM-2008-REPLY TO HEARING(8-10-2013).pdf 09 Aug 2018
11 1856-MUM-2008-REPLY TO EXAMINATION REPORT(22-1-2013).pdf 09 Aug 2018
12 1856-MUM-2008-FORM 5(18-8-2009).pdf 09 Aug 2018
13 1856-mum-2008-form 3.pdf 09 Aug 2018
14 1856-MUM-2008-FORM 3(23-3-2011).pdf 09 Aug 2018
15 1856-MUM-2008-FORM 3(2-9-2008).pdf 09 Aug 2018
16 1856-mum-2008-form 2.pdf 09 Aug 2018
18 1856-mum-2008-form 2(title page).pdf 09 Aug 2018
19 1856-MUM-2008-FORM 2(TITLE PAGE)-(PROVISIONAL)-(2-9-2008).pdf 09 Aug 2018
20 1856-MUM-2008-FORM 2(TITLE PAGE)-(GRANTED)-(9-9-2014).pdf 09 Aug 2018
21 1856-MUM-2008-FORM 2(TITLE PAGE)-(COMPLETE)-(18-8-2009).pdf 09 Aug 2018
22 1856-MUM-2008-FORM 2(PROVISIONAL)-(2-9-2008).pdf 09 Aug 2018
23 1856-MUM-2008-FORM 2(GRANTED)-(9-9-2014).pdf 09 Aug 2018
24 1856-MUM-2008-FORM 2(COMPLETE)-(18-8-2009).pdf 09 Aug 2018
25 1856-MUM-2008-FORM 18(8-12-2009).pdf 09 Aug 2018
26 1856-mum-2008-form 1.pdf 09 Aug 2018
27 1856-MUM-2008-DESCRIPTION(PROVISIONAL)-(2-9-2008).pdf 09 Aug 2018
28 1856-MUM-2008-DESCRIPTION(GRANTED)-(9-9-2014).pdf 09 Aug 2018
29 1856-MUM-2008-DESCRIPTION(COMPLETE)-(18-8-2009).pdf 09 Aug 2018
30 1856-mum-2008-correspondence.pdf 09 Aug 2018
31 1856-MUM-2008-CORRESPONDENCE(IPO)-(9-9-2014).pdf 09 Aug 2018
32 1856-MUM-2008-CORRESPONDENCE(8-12-2009).pdf 09 Aug 2018
33 1856-MUM-2008-CORRESPONDENCE(7-4-2010).pdf 09 Aug 2018
34 1856-MUM-2008-CORRESPONDENCE(23-3-2011).pdf 09 Aug 2018
35 1856-MUM-2008-CORRESPONDENCE(18-8-2009).pdf 09 Aug 2018
36 1856-mum-2008-claims.pdf 09 Aug 2018
38 1856-MUM-2008-CLAIMS(PROVISIONAL)-(2-9-2008).pdf 09 Aug 2018
39 1856-MUM-2008-CLAIMS(MARKED COPY)-(8-10-2013).pdf 09 Aug 2018
40 1856-MUM-2008-CLAIMS(MARKED COPY)-(22-1-2013).pdf 09 Aug 2018
41 1856-MUM-2008-CLAIMS(GRANTED)-(9-9-2014).pdf 09 Aug 2018
42 1856-MUM-2008-CLAIMS(COMPLETE)-(18-8-2009).pdf 09 Aug 2018
43 1856-MUM-2008-CLAIMS(AMENDED)-(8-10-2013).pdf 09 Aug 2018
44 1856-MUM-2008-CLAIMS(AMENDED)-(22-1-2013).pdf 09 Aug 2018
45 1856-MUM-2008-ABSTRCT(COMPLETE)-(18-8-2009).pdf 09 Aug 2018
46 1856-mum-2008-abstract.pdf 09 Aug 2018
48 1856-MUM-2008-ABSTRACT(PROVISIONAL)-(2-9-2008).pdf 09 Aug 2018
49 1856-MUM-2008-ABSTRACT(GRANTED)-(9-9-2014).pdf 09 Aug 2018

ERegister / renewals

Ceased

No renewals recorded.